• Medical_Professionals
• Medical_students
• Nurses

3rd Annual Advances in Immuno-Oncology Congress is organized by Oxford Global Marketing Ltd and will be held during May 24 - 25, 2018 at London, England, United Kingdom. 

Delegates will benefit from:

• An executive format providing intimate interaction with industry peers’ ideas and experiences through case study presentations and panel discussions

• Networking opportunities and sharing ideas with other senior peers

• Pre-scheduled one-to-one meetings between you and solution providers will provide you with an opportunity to forge partnerships and discover solutions

• Post-event follow up offering all documentation from the meeting and re-booking discounts

• Tailor-made agenda – hand pick any conference and panel sessions you wish to attend

Stefan Glück, Vice President Global Medical Affairs

Celgene

Timothy Herpin, Vice President, Head of Transactions, Business Development

AstraZeneca

Kandeepan Ganeshalingam, Executive Director, Therapeutic Area Head Oncology

MSD

Kenneth Emancipator, Executive Medical Director and Head of Companion Diagnostics

Merck

Jianda Yuan, Senior Director, Translational Immuno-Oncolology Research

Merck

Sara Brett, Director Translational Immunology

GlaxoSmithKline

Roman Kischel, Director Research – BiTE Technology

Amgen

Maria Groves, Associate Director, Lab Head for the CRUK/MedImmune Alliance

MedImmune

Eric Hatterer, Head, In Vitro Pharmacology, ESTM Department

NovImmune

Krysztof Masternak, Head of Biology

NovImmune

Carola Ries, Head of Cancer Immunotherapy

Roche

Sophie Wildsmith, Diagnostic Expert; Oncology, Personalised Healthcare and Biomarkers

AstraZeneca

Grace Macaulay, Global Safety Physician, Patient Safety-Oncology

MedImmune

Troels Jordansen, Chief Executive Officer

Glycostem Therapeutics

Dolores Schendel, Chief Executive Officer & Chief Scientific Officer

Medigene

Julio Castro, Chief Executive Officer

Palobiofarma

Bruce Roberts, Chief Scientific Officer

Vedanta Biosciences

Frederic Triebel, Chief Scientific Officer & Chief Medical Officer

Immutep Ltd.

Agnete Fredriksen, Chief Scientific Officer

Vaccibody AS

David Urech, Co-Chief Executive Officer and Chief Scientific Officer

Numab Therapeutics AG

Takashi Kishimoto, Chief Scientific Officer

Selecta Biosciences, Inc.

Geert Mudde, Chief Scientific Officer

OncoQR

Jonathan Pachter, Chief Scientific Officer

Verastem, Inc.

Igor Matushansky, Chief Medical Officer

Hookipa Biotech

Ely Benaim, Chief Medical Officer

Rexahn Pharmaceuticals

Jonathan Zalevsky, Senior Vice President, Biology & Preclinical Development

Nektar Therapeutics

James Legg, Vice President, R&D

Crescendo Biologics

Sreesha Srinivasa, Associate Vice President, Head – Translational Research

Biocon Research Ltd.

Tim Wyant, Senior Director of Cancer Immunology

Curis

Markus Zettl, Director, Immuno-Oncology

Pieris Pharmaceuticals

Joanne Bedwell-Garner, Development Director

Macrophage Pharma

Richard C. A. Sainson, Director of Pharmacology and Translational Sciences

Kymab

Haining Huang, Director, Immuno-Oncology

Oxford Biotherapeutics

Steven Shaw, Director of Translational Medicine

BioLineRx Ltd.

Wendy Broom, Associate Director, Discovery

Genocea Biosciences

Shimobi Onuoha, Associate Director, Binder Discovery

Autolus Ltd.

Patrik Kehler, Head of Immuno-Oncology

Glycotope GmbH

Tom Holdich, Head of Global Medical Affairs & EU Clinical Development

Adaptimmune

Philipp Mueller, Principal Scientist

Boehringer Ingelheim

Christoph Goletz, Senior Scientist, Immuno-Oncology

Glycotope GmbH

Paul Sondel, Reed and Carolee Walker Professor of Pediatrics, Human Oncology and Genetics

University of Wisconsin

Nelson Tang, Professor of Allergy and Immunology

Chinese University of Hong Kong

Awen Gallimore, Professor of Medicine

University of Cardiff

2017 Speakers Included:

Philip Arlen, President and CEO

Precision Biologics, Inc.

Alan Graham Pockley, Professor & Director

Nottingham Trent University, multimmune GmbH

Ulf Grawunder, CEO

NBE Therapeutics

Karen LaRochelle, Chief Business Officer

PsiOxus Therapeutics

Jonathan Zalevsky, Vice President, Biology & Preclinical Development

Nektar Therapeutics

Timothy Herpin, Vice President, Head of Transactions, Business Development

AstraZeneca

Jacqueline Doody, Vice President, Immunology

F-star Biotechnology Ltd.

Christopher Heery, Chief Medical Officer

Bavarian Nordic

Christophe Queva, Chief Scientific Officer

iTeos Therapeutics

James Legg, Director

Crescendo Biologics

Pieter Fokko van Loo, Director

Merus Pharmaceuticals

Markus Mohrs, Director, Immuno-Oncology

Regeneron Pharmaceuticals

Marlon J. Hinner, Director of Immuno-oncology

Pieris Pharmaceuticals

Chan Whiting, Director of Immune Monitoring and Biomarker Development

Aduro Biotech

Peter Dudek, Principal

Wellington Partners Life Science Venture Capital

Cedrik Britten, VP, Head of Oncology Cell Therapy DPU, Oncology R&D

GlaxoSmithKline

Regina Heidenreich, Head of Immunotherapy

CureVac GmbH

Guillaume Vignon, Global Head of Immuno-Oncology Licensing & Business Development

Merck KGaA

David Krige, Head of Biomarkers

Immunocore Ltd.

Geert. C. Mudde, Founder and CSO

OncoQR ML GmbH

Nicolas Poirier, Chief Scientific Officer

OSE Immunotherapeutics

Dan Williams, Head, UK Research Operations

Adaptimmune

Bruno Gomes, Head of Tumor Immunology

iTeos Therapeutics

Alfonso Quintas, Global Clinical Leader, Oncology,

Novartis Institute for Biomedical Research

Saso Cemerski, Principal Scientist

MSD

Brian Haines, Principal Scientist in Vivo Pharmacology

MSD Research Laboratories

Matthew Albert, Principal Scientist, Cancer Immunology

Genentech

Elena Brin, Research Fellow

Polaris Pharmaceuticals

Luca Melchiori, Group Leader, T Cell Correlate Research

Adaptimmune

Sara Colombetti, Group Leader

Roche Innovation Center Zürich

Mike Giffin, Senior Scientist

Amgen

Pushpa Jayaraman, Investigator III

Novartis Institutes for BioMedical Research (NIBR)

Christian Schmees, Head of Tumor Biology

NMI Reutlingen

Ravi Madan, Clinical Director, Genitourinary Malignancies Branch

National Cancer Institute, National Institutes of Health

Lenny Shultz, Professor

The Jackson Laboratory

Paul M. Sondel, Reed and Carolee Walker Professor of Pediatrics, Human Oncology, and Genetics

University of Wisconsin

Hardev Pandha, Professor of Medical Oncology

University of Surrey

Winald Gerritsen, Professor of Tumour Immunotherapy

Radboud University Medical Centre Nijmegen

Silvia Formenti, Sandra and Edward Meyer Professor of Cancer Research, Chairman, Department of Radiation Oncology, Associate Director, Meyer Cancer Center

Weill Cornell Medical College

Sophia Karagiannias, Reader in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, St. John’s Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine

King’s College London

Ahuva Nissim, Reader in Antibody and Therapeutic Engineering Biochemical Pharmacology

Queen Mary University of London

Jeanette Leusen, Head Immunotherapy Group of the Laboratory for Translational Immunology

University Medical Center Utrecht

Dominic Eisinger, Vice President of Sales and Marketing

MyRIAD RBM

Steven M. Anderson, Senior Vice President

Covance

Marie Cumberbatch, Consultant to Histologix, Director

Immune Insight Limited

Alison O’Mahony, Vice President R&D Research Biology

DiscoverX

Stephen Anderton, Chief Scientific Officer

Aquila Biomedical

Neil Williams, Founder and Chief Scientific Officer

KWS BioTest

GBP

Group registrations not allowed

Accompanying persons not allowed

We don’t accept Online Abstracts

Oxford Global have been made aware of a service provider under the name Exhibition Housing Services (EHS), which has contacted a number of companies who are supporting or attending the Advances in Immuno-oncology Congress, to offer hotel reservation services.

Please note that Exhibition Housing Services do not represent Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to exhibitors.

If you are contacted by Exhibition Housing Services by phone or email using Oxford Global’s name or the name of the Advances in Immuno-oncology Congress and offering hotel reservation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by EHS or entering into any conversation with EHS or replying to any EHS emails sent from ‘@ehshousing.com’.

EHS offer a pre-paid hotel reservation service and we believe that exhibitors and attendees need to be extremely careful when dealing with EHS as a booking fee is charged in addition to the hotel price. In addition it appears that any credit cards used to secure bookings will be immediately used for taking 25% of value of booking and once any exhibitor or attendee have confirmed that he / she wishes to go ahead with the accommodation booking full payment is taken. EHS also operate very stringent cancellation policies.

Submission Info

For attendees interested in submitting a poster, there are opportunities now available. Your poster presentation will be located in the exhibition room for two days alongside other posters from senior scientists working in industry and academia.

How to submit your abstract

We will require:

Poster title

Abstract (200 words or less)

Principal author

Organisation

Mailing address

Email

Telephone

Fax

Additional authors

In order to secure your board space a fee of £250 plus VAT will be required. The poster should be presented as A0 (841mm x 1189mm) portrait size.

To take advantage of this opportunity you need to be registered as a paid delegate over the 2 days. We have limited spaces available, to register please click on book online or for more information please call +44 (0)1865 248455.

Oxford Global’s events are the perfect platform to stimulate lead generation, partnership formation, brand building and global business deals. They provide shortened sales cycles and measurable ROI.

Sponsorships are highly effective in enabling market immersion & visibility, direct access to existing clients and potential customers alongside dedicated face to face meeting time with important targets.

Alternatively, contact sponsorship@oxfordglobal.co.uk

• Fluidigm
  

  

  Fluidigm is committed to empowering the cancer immunotherapy community with research tools to interrogate the tumor microenvironment with unprecedented resolution. Whether you seek to target new biomarkers or to optimize the effectiveness of checkpoint inhibitors, CAR T cells or cancer vaccines, Fluidigm can help you reach your next research breakthrough.

• ImmunXperts
  

  

  ImmunXperts, a young company with a rich history, offers services to support you in the risk assessment and mitigation of your drug candidate’s immunogenicity profile, the functional screening of your immuno-oncology candidates and the development of potency assays for stem cells. We also provide services for the isolation and cryopreservation of biological samples and we offer support and training with assay development. In collaboration with our scientific advisors and international partners, ImmunXperts offers access to a unique team of seasoned immunology experts. Our partnership model allows us to tap into a broad network of subcontractors and academic collaborators, resulting in a wide range of technologies and broad service offering. We think with you!

• Myriad RBM
  

  

  Myriad RBM, Inc. is the world’s leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on its Multi-Analyte Profiling (MAP) technology platform. This platform provides clinical researchers with reproducible and quantitative data for a few or hundreds of proteins in a cost-effective manner.  All services are performed in our CLIA certified laboratory.  As a guide to drug development researchers, Myriad RBM also offers Strategic Biomarker Services that include companion diagnostics, custom assay development, co-sponsored research programs, and innovative cell culture products.  Myriad RBM’s biomarker testing laboratory is located in Austin, TX. Myriad RBM is a wholly owned subsidiary of Myriad Genetics, Inc. (MYGN), a leading molecular diagnostic company based in Salt Lake City, Utah which develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests.

• ProQinase
  

  

  ProQinase is a leading CRO for anti-cancer drug discovery providing customized solutions from primary compound screening to in vivo proof of concept. Apart from integrated drug discovery projects as a “one-stop shop” solution provider, ProQinase also carries out single service solutions.

  A main focus of ProQinase’s expertise is a versatile immuno-oncology platform based on syngeneic mouse models (subcutaneous, orthotopic, metastasis) which can be analysed via flow cytometry, bioluminescence imaging, histology and further methods.

  In addition, ProQinase offers xenograft mouse models as well as cell-based and biochemical assays. Our strengths are custom-tailored solutions for testing your drug or immunotherapeutic.

  One of the latest innovative developments at ProQinase is a series of new tumor graft models from spontaneously arisen or carcinogen-induced malignant tissues (Carcinogen-Induced or Spontaneous Mouse-Derived Isografts, cMDI or sMDI, respectively). The tumors are propagated in mice only (i.e. without cell culture), and hence original tumor characteristics including original intratumoral immune cell populations are maintained

• Tissue Solutions
  

  

• Ultivue
  

  

  Ultivue’s proprietary reagents, instruments, and bioinformatics tools will enable researchers and clinicians to realize the promise of personalized medicine through better matching of patients to therapeutic options.  In 2017, the company is launching products and services that seamlessly integrate into existing workflows for biomarker discovery, assay validation, and companion diagnostic applications.

Contact No.: +44 (0)1865 248455

Email: info@oxfordglobal.co.uk